Predictive Value of Cardiovascular Risk Functions: Limitations and Future Potential;Capacidad predictiva de las funciones de riesgo cardiovascular: limitaciones y oportunidades

Revista Espanola de Cardiologia Suplementos

Volumn 9, Issue 2, 2009, Pages 4-13

  Baena Díez, José M ^a,b   Ramos, Rafael ^a,b   Marrugat, Jaume ^b  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Cardiovascular risk factors; Coronary heart disease risk functions; Primary prevention

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY RISK; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; PRIMARY PREVENTION; RELIABILITY; RISK ASSESSMENT;

EID: 67649380363     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1131-3587(09)71500-6     Document Type: Article

References (67)

1. Pérez G., Pena A., Sala J., Roset P., Masiá R., and Marrugat J. Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in Gerona, Spain, 1990-1992. Int J Epidemiol 27 (1998) 599-604
2. Tunstall-Pedoe H., Kuulasmaa K., Mahönen M., Tolonen H., Ruokokoski E., Philippe Amouyel, and WHO MONICA Project. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet 353 (1999) 1547-1557
3. Marrugat J., Elosua R., and Martí H. Epidemiología de la cardiopatía isquémica en España: estimación del número de casos y de las tendencias entre 1997 y 2005. Rev Esp Cardiol 55 (2002) 337-346
4. Villar Álvarez F., Banegas Banegas J.R., De Mata Donado Campos J., and Rodríguez Artalejo F. Las enfermedades cardiovasculares y sus factores de riesgo en España: hechos y cifras. Informe SEA 2003 (2003), Ergón, Madrid
5. Prevention of coronary heart disease Report of a WHO Expert Committee. WHO Technical Report Series 6-7-8. Geneva: World Health Organisation: 1982.
6. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial. Risk Factor Changes and Mortality Results. JAMA 248 (1982) 1465-1477
7. Miguel Gracía F., Maderuelo Fernández J.A., and García Ortiz A. Riesgo cardiovascular: concepto, estimación, usos y limitaciones. AMF 4 (2008) 423-433
8. Grau M., and Marrugat J. Funciones de riesgo en la prevención primaria de las enfermedades cardiovasculares. Rev Esp Cardiol 61 (2008) 404-406
9. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart. 2006; 91 Suppl V:v1-52.
10. Baena Díez J.M., Alvarez Pérez B., Piñol Forcadell P., Martín Peñacoba R., Nicolau Sabaté M., Altès Boronat A., et al. Association between clustering of cardiovascular risk factors and the risk of cardiovascular disease. Rev Esp Salud Publica 76 (2002) 7-15
11. Ramos R., Marrugat J., Basagaña X., Sala J., Masiá R., Elosua R., and REGICOR Investigators. The role of age in cardiovascular risk factor clustering in non-diabetic population free of coronary heart disease. Eur J Epidemiol 19 (2004) 299-304
12. Wilson P.W.F., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
13. Marrugat J., D'Agostino R., Sullivan L., Elosua R., Wilson P., Ordovas J., et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 57 (2003) 634-638
14. Conroy R.M., Pyörälä K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24 (2003) 987-1003
15. Assmann G., Cullen P., and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105 (2002) 310-315
16. Gaziano T.A., Young C.R., Fitzmaurice G., Atwood S., and Gaziano M. Laboratory-based versus non-laboratory-based methods for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 371 (2008) 923-931
17. D'Agostino R., Vasan R.M., Pencina M.J., Wolf P.A., Cobain M., Massaro J.M., et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation 117 (2008) 743-753
18. Hippisley-Cox J., Coupland C., Vinogradova Y., Rogson J., May M., and Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 335 (2007) 136
19. Daviglus M.L., Lloyd-Jones D.M., and Pirzada A. Preventing cardiovascular disease in the 21st century. Am J Cardiovasc Drugs 6 (2006) 87-101
20. Baena Díez J.M., García Lareo M., De la Poza Abad M., Hernández Ibáñez R., Muñoz Rubio A., and García Rey Z. Estimación de riesgo cardiovascular global a partir del riesgo coronario. Estudio de cohortes. Med Clin (Barc) 127 (2006) 8-10
21. Marin A., Medrano M.J., González J., Pintado H., Compaired V., Bárcena M., et al. Risk of ischaemic heart disease and acute myocardial infarction in a Spanish population: observational prospective study in a primary-care setting. BMC Public Health 6 (2006) 38
22. Liao Y., McGee D.L., Cooper R.D., and Sutkowski M.B.E. How generalizable are coronary risk prediction models? Comparison of Framingham and Two national cohorts. Am Heart J 84 (1999) 31-36
23. D'Agostino Sr. R.B., Grundy S., Sullivan L.M., Wilson P., and CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286 (2001) 180-187
24. Thomsen T.F., McGee D., Davidsen M., and Jørgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 31 (2002) 817-822
25. Empana J.P., Ducimetière P., Arveiler D., Ferrières J., Evans A., Ruidavets J.B., et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 24 (2003) 1903-1911
26. Hense H.W., Schulte H., Löwel H., Assmann G., and Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany -results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 24 (2003) 937-945
27. Brindle P., Emberson J., Lampe F., Walker M., Whincup P., Fahey T., et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 327 (2003) 1267
28. Marrugat J., Subirana I., Comín E., Cabezas C., Vila J., Elosua R., et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA study. J Epidemiol Community Health 61 (2007) 40-47
29. Cooper J.A., Miller G.J., and Humphries S.E. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis 181 (2005) 93-100
30. Liu J., Hong Y., D'Agostino Sr. R.B., Wu Z., Wang W., Sun J., et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 291 (2004) 2591-2599
31. Ferrario M., Chiodini P., Chambless L.E., Cesana G., Vanuzzo D., and Panico S. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol 34 (2005) 413-421
32. Ridker P.M., Buring J.E., Rifai N., and Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297 (2007) 611-619
33. Aspelund T., Thorgeirsson G., Sigurdsson G., and Gudnason V. Estimation of 10-year risk of fatal cardiovascular disease and coronary heart disease in Iceland with results comparable with those of the Systematic Coronary Risk Evaluation project. Eur J Cardiovasc Prev Rehabil 14 (2007) 761-768
34. Marrugat J., D'Agostino R., Sullivan L., Elosua R., Wilson P., Ordovas J., et al. An adaptation of the Framingham coronary risk function to southern Europe Mediterranean areas. J Epidemiol Community Health 57 (2003) 634-638
35. Jackson P.R., Wallis E.J., Haq I.U., and Ramsay L.E. HMG CoA reductase inhibitors (statins) for primary prevention: at what coronary risk is safety assured?. Br J Clin Pharmacol 52 (2001) 439-446
36. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 28 (2007) 2375-2414
37. Thavendiranathan P., Bagai A., Brookhart A., and Choudhry N. Primary prevention of cardiovascular diseases with statin therapy. A meta-analysis of randomized controlled trials. Arch Intern Med 166 (2006) 2307-2313
38. Anderson K.M., Wilson P.W.F., Odell P.M., and Kannel W.B. An update coronary risk profile. A statement for health professionals. Circulation 83 (1991) 356-362
39. Donnan P.T., Donnelly L., New J.P., and Morris A.D. Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population. Diabetes Care 29 (2006) 1231-1236
40. Simon A., Chironi G., and Levenson J. Comparative performance of subclinical atherosclerosis test in predicting coronary heart disease in asymptomatic individuals. Eur Heart J 28 (2007) 2967-2971
41. Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality. JAMA 300 (2008) 197-208
42. Baena-Díez J., Arboix A., Merino-Audi M., Tomàs-Pelegrina F., Ellacuría-Torres A., García-Lareo M., et al. La glucemia basal alterada es un factor de riesgo para el infarto cerebral aterotrombótico o lacunar. Estudio de casos y controles. Neurologia 24 (2008) 24-29
43. Gerstein H.C., Pais P., Pogue J., and Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction. A case-control study. J Am Coll Cardiol 33 (1999) 612-619
44. Fisman E.Z., Motro M., Tenenbaum A., Boyko V., Maldelzweig L., and Behar S. Impaired fasting glucose concentrations in nondiabetic patiens with ischemic heart disease: a marker for a worse prognosis. Am Heart J 141 (2001) 485-490
45. Tanne D., Koren-Morag N., and Goldbourt U. Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: a prospective cohort study. Stroke 35 (2004) 2351-2355
46. Thrainsdottir I.S., Aspelund T., Gudnason V., Malmberg K., Sigurdsson G., Thorgeirsson G., et al. Increasing glucose levels and BMI predict future heart failure experience from the Reykjavík Study. Eur J Heart Fail 9 (2007) 1051-1057
47. De Koning L., Merchant A.T., Pogue J., and Anand S.S. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J 28 (2007) 850-856
48. Pischon T., Boeing H., Hoffmann K., Bergmann M., Schulze M.B., Overvad K., et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 359 (2008) 2105-2120
49. Weiner D.E., Tighiouart H., Amin M.G., Stark P.C., MacLeod B., and Griffith J.L. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 15 (2004) 1307-1331
50. Weir M.R. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2 (2007) 581-590
51. American Diabetes Association. Aspirin therapy in diabetes (Position Statement). Diabetes Care Suppl 1 (2003) S87-S88
52. Ogawa H., Nakayama M., Morimoto T., Uemura S., Kanauchi M., Doi N., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300 (2008) 2134-2141
53. Calverley P.M., and Scott S. Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events?. COPD 3 (2006) 233-242
54. Gabriel S.E. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 121 Suppl (2008) S9-S14
55. Dorn S.D., and Sandler R.S. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol 102 (2007) 662-667
56. Morrison A.C., Bare L.A., Chambless L.E., Ellis S.G., Malloy M., Kane J.P., et al. Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 166 (2007) 28-35
57. Lloyd-Jones D.M., Nam B.H., D'Agostino Sr. R.B., Levy D., Murabito J.M., Wang T.J., et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 291 (2004) 2204-2211
58. Kathiresan S., Melander O., Anevski D., Guiducci C., Burtt N.P., Roos C., et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358 (2008) 1240-1249
59. Paynter N.P., Chasman D.I., Buring J.E., Shiffman D., Cook N.R., and Ridker P.M. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med 150 (2009) 65-72
60. Helgadottir A., Thorleifsson G., Manolescu A., Gretarsdottir S., Blondal T., Jonasdottir A., et al. A common variante on chromosome 9p21 affects the risk of myocardial infarction. Science 316 (2007) 1491-1493
61. McPherson R., Pertsemlidis A., Kavaslar N., Stewart A., Roberts R., Cox D.R., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 316 (2007) 1488-1491
62. Samani N.J., Erdmann J., Hall A.S., Hengstenberg C., Mangino M., Mayer B., et al. Genomewide association analysis of coronary artery disease. N Engl J Med 357 (2007) 443-453
63. Myocardial Infarction Genetics Consortium. Genome-wide association of early-onset myocardial infarction with common single nucleotide polymorphisms, common copy number variants, and rare copy number variants. Nat Genet. 2009 [en prensa].
64. Sofi F., Capalbo A., Cesari F., Abbate R., and Gensini G.F. Physical activity during leisure time and primary prevention of coronary heart disease: an updated meta-analysis of cohort studies. Eur J Cardiovasc Prev Rehabil 15 (2008) 247-257
65. Trichopoulou A., Costacou T., Bamia C., and Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 348 (2003) 2599-2608
66. Anderson K.M., Castelli W.P., and Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA 257 (1987) 2176-2180
67. Marrugat J., and Sala J. Nuevos instrumentos y los riesgos de siempre. Rev Esp Cardiol 60 (2007) 464-467